透明質酸在醫療保健中的應用：全球市場

全球透明質酸醫療產品市場預計將從 2025 年的 80 億美元成長到 2030 年底的 105 億美元，2025 年至 2030 年的複合年成長率為 5.7%。

北美透明質酸醫療產品市場預計將從 2025 年的 34 億美元成長到 2030 年底的 41 億美元，2025 年至 2030 年的複合年成長率為 3.5%。

亞太地區透明質酸醫療產品市場預計將從 2025 年的 17 億美元成長到 2030 年底的 28 億美元，2025 年至 2030 年的複合年成長率為 10.1%。

調查範圍

本報告概述了全球透明質酸 (HA) 醫療（或保健）產品市場，並分析了當前的市場趨勢。本報告涵蓋的 HA 醫療產品包括 HA 真皮填充劑、黏彈性補充劑、乾眼症治療眼科黏彈劑(OVD)、用於傷口護理和肌肉骨骼修復的再生產品、粘連屏障以及用於泌尿系統的填充劑。本報告僅涵蓋由合格醫療保健專業人員在門診或外科環境中使用或建議的處方產品。

該報告對 HA 醫療產品市場的估計包括 2024 年基準年的全球收益（百萬美元）、2025 年的估計值以及 2025-2030 年的預測數據。報告重點關注關鍵市場趨勢、課題、機會和供應商格局。報告還涵蓋了與市場相關的新產品、收購和合作夥伴關係。報告也分析了環境、社會和企業管治(ESG) 的發展。

競爭格局分析包括每個 HA 醫療產品市場主要企業的市場佔有率排名，並且還有一個部分介紹主要企業。

報告內容

• 透明質酸（HA）醫療產品全球市場概覽
• 全球市場趨勢的詳細分析，包括 2022 年至 2024 年的歷史收益數據、2025 年的估計值以及 2030 年的預測以及預計的複合年成長率
• 透過考慮市場中存在的微觀和宏觀環境因素以及回顧波特五力模型和行業供應鏈分析來分析市場機會
• 市場促進因素、限制因素以及其他影響全球市場的因素的說明
• 涵蓋不斷發展的技術、當前和未來的市場潛力、研發活動、成長策略、法律規範和報銷方案以及市場中的 ESG 趨勢
• 透過專有技術、併購和策略舉措，確定最有能力滿足這項需求的公司
• 永續性趨勢和 ESG 發展概述，重點在於消費者態度、ESG 風險評估和主要企業的實踐
• 相關專利分析重點突出已授權和已公佈的關鍵專利
• 全球主要公司簡介，包括 AbbVie Inc.、Galderma、Sanofi、Bioventus、IBSA Institut Biochimique SA 和 Fidia Farmaceutici SpA

目錄

第1章摘要整理

第2章 市場概況

• 玻尿酸
• 宏觀經濟因素分析
• 經濟成長和收入水平
• 美國關稅的影響
• 人口趨勢
• 波特五力分析

第3章 市場動態

• 市場動態
• 市場促進因素
• 擴大透明質酸的臨床應用
• 創新和生物技術進步
• 微創手術的趨勢
• 市場課題
• HA高成本且效果短期
• 潛在的不良反應和副作用
• 市場趨勢
• 微生物發酵生產玻尿酸
• 玻尿酸混合配方

第4章：監理現狀

• 概述
• 美國
• EU
• 日本
• 中國

第5章 新興技術與發展

• 透明質酸作為藥物傳遞載體
• 3D生物列印
• 基於酵素的透明質酸合成
• 臨床試驗分析
• 關鍵要點

第6章市場區隔分析

• 部門市場
• 全球醫療保健領域的透明質酸市場（按產品）
• 真皮填充劑
• 黏稠補充劑
• 眼科產品
• 再生及防沾黏產品
• 泌尿系統填充劑
• 全球透明質酸醫療保健市場（按來源）
• 動物源性玻尿酸
• 微生物發酵
• 地理分佈
• 全球醫療保健領域透明質酸市場（按地區）
• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 南美洲

第7章 競爭訊息

• 透明質酸真皮填充劑
• 關鍵要點
• 市佔率分析
• 黏稠補充劑
• 關鍵要點
• 市佔率分析
• 眼科產品
• 再生及防沾黏產品
• 泌尿系統填充劑

第8章 玻尿酸市場的永續性：ESG 視角

• ESG介紹
• 透明質酸市場特有的關鍵 ESG 議題
• HA 治療中一次性塑膠對環境的影響
• 大規模微生物透明質酸生產的環境課題
• 品管在注射透明質酸安全的重要作用
• 結論

第9章 附錄

• 調查方法
• 資訊來源
• 簡稱
• 公司簡介
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ANIKA THERAPEUTICS INC.
• BIOVENTUS
• FERRING BV
• FIDIA FARMACEUTICI SPA
• GALDERMA
• IBSA INSTITUT BIOCHIMIQUE SA
• MEDYTOX
• MERZ PHARMA
• NORDIC PHARMA
• SANOFI
• SANTEN PHARMACEUTICAL CO. LTD.
• SEIKAGAKU CORP.
• TEOXANE
• URSAPHARM ARZNEIMITTEL GMBH
• 新興Start-Ups/市場顛覆者

The global market for hyaluronic acid medical products is estimated to grow from $8 billion in 2025 to $10.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2030.

The North American market for hyaluronic acid medical products is estimated to grow from $3.4 billion in 2025 to $4.1 billion by the end of 2030, at a CAGR of 3.5% from 2025 to 2030.

The Asia-Pacific market for hyaluronic acid medical products is estimated to grow from $1.7 billion in 2025 to $2.8 billion by the end of 2030, at a CAGR of 10.1% from 2025 to 2030.

Report Scope

This report offers an overview of the global market for hyaluronic acid (HA) medical (or healthcare) products while also analyzing current market trends. The HA medical products covered in this report include HA dermal fillers, viscosupplements, dry eye treatments, ophthalmic viscoelastic devices (OVDs), regenerative products for wound care and musculoskeletal repair, anti-adhesion barriers and bulking agents for urology applications. The report covers only prescription products that may be used or recommended exclusively by qualified healthcare professionals in outpatient settings or during surgical procedures.

The report's estimates of the HA medical products market include global revenue ($ millions) for the base year of 2024, estimates for 2025 and data for the forecast period of 2025 through 2030. The report focuses on the major trends, challenges and opportunities in the market and vendor landscape. It also covers the new products, acquisitions and collaborations related to the market. The report also analyzes environmental, social and corporate governance (ESG) developments.

The report concludes with an analysis of the competitive landscape, which provides a ranking by market share of leading companies in each HA medical product market. There is also a section of profiles of the leading companies.

Report Includes

• An overview of the global market for hyaluronic acid (HA) medical products
• In-depth analysis of global market trends, featuring historical revenue data from 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of compound annual growth rates (CAGRs) through 2030
• Analysis of market opportunities with a review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, and strategic initiatives
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Profiles of the leading global companies, including AbbVie Inc., Galderma, Sanofi, Bioventus, IBSA Institut Biochimique S.A., and Fidia Farmaceutici S.p.A.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics
• Emerging Trends
• Analysis by Segment
• Analysis by Region
• Conclusion

Chapter 2 Market Overview

• Hyaluronic Acid
• Analysis of Macroeconomic Factors
• Economic Growth and Income Levels
• Impact of the U.S. Tariffs
• Demographic Trends
• Porter's Five Forces Analysis
• Bargaining Power of Buyers: Moderate to High
• Bargaining Power of Suppliers: Moderate
• Threat of New Entrants: Moderate
• Threat of Substitutes: Moderate to High
• Industry Rivalry: Moderate

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Expanding Clinical Applications of Hyaluronic Acid
• Innovation and Biotechnological Advancements
• Trend Toward Minimally Invasive Procedures
• Market Challenges
• High Cost and Short-Lasting Effects of HA
• Potential Adverse Reactions and Side Effects
• Market Trends
• Microbial Fermentation-based HA Production
• Hybrid Formulations of HA

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• European Union
• Japan
• China

Chapter 5 Emerging Technologies and Developments

• Hyaluronic Acid as a Drug Delivery Vehicle
• Three-Dimensional Bioprinting
• Enzyme-based Hyaluronic Acid Synthesis
• Clinical Trial Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Hyaluronic Acid in Healthcare, by Product
• Dermal Fillers
• Viscosupplements
• Ophthalmic Products
• Regenerative and Anti-Adhesion Products
• Bulking Agents for Urology Applications
• Global Market for Hyaluronic Acid in Healthcare, by Source
• Animal-derived HA
• Microbial Fermentation
• Geographic Breakdown
• Global Market for Hyaluronic Acid in Healthcare, by Region
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Hyaluronic Acid Dermal Fillers
• Key Takeaways
• Market Share Analysis
• Viscosupplements
• Key Takeaways
• Market Share Analysis
• Ophthalmic Products
• Regenerative and Anti-Adhesion Products
• Bulking Agents for Urology Applications

Chapter 8 Sustainability in Hyaluronic Acid Market: An ESG Perspective

• Introduction to ESG
• Key ESG Issues Specific to Hyaluronic Acid Market
• Environmental Impact of Single-Use Plastics in HA-based Treatments
• Environmental Challenges of Large-Scale Microbial HA Production
• Critical Role of Quality Control in Injectable HA Safety
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Information Sources
• Abbreviations
• Company Profiles
• ABBVIE INC.
• ANIKA THERAPEUTICS INC.
• BIOVENTUS
• FERRING B.V.
• FIDIA FARMACEUTICI S.P.A.
• GALDERMA
• IBSA INSTITUT BIOCHIMIQUE SA
• MEDYTOX
• MERZ PHARMA
• NORDIC PHARMA
• SANOFI
• SANTEN PHARMACEUTICAL CO. LTD.
• SEIKAGAKU CORP.
• TEOXANE
• URSAPHARM ARZNEIMITTEL GMBH
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Hyaluronic Acid Medical Products, by Region, Through 2030
• Table 1 : Global Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 2 : Global Nonsurgical Procedures Performed by Plastic Surgeons, 2022 versus 2023
• Table 3 : Global Minimally Invasive Cosmetic Procedures, 2024 versus 2023
• Table 4 : Commercially Available Hyaluronic Acid Dermal Fillers
• Table 5 : Global Market for Dermal Fillers, by Region, Through 2030
• Table 6 : Global Market for Viscosupplements, by Region, Through 2030
• Table 7 : Commercially Available Three-Injection Regimen Viscosupplements
• Table 8 : Commercially Available Single-Injection Regimen HA Viscosupplements
• Table 9 : Commercially Available Five-Injection Regimen HA Viscosupplements
• Table 10 : Global Market for Viscosupplements, by Regimen Type, Through 2030
• Table 11 : Global Market for Ophthalmic Products, by Region, Through 2030
• Table 12 : Global Market for Ophthalmic Products, by Type, Through 2030
• Table 13 : Commercially Available Ophthalmic Viscosurgical Devices (OVDs)
• Table 14 : Commercially Available Prescription Regenerative Solutions
• Table 15 : Commercially Available Prescription Anti-Adhesion Products
• Table 16 : Global Market for Regenerative and Anti-Adhesion Products, by Region, Through 2030
• Table 17 : Commercially Available HA-Based Bulking Agents for Urology Applications
• Table 18 : Global Market for Bulking Agents for Urology Applications, by Region, Through 2030
• Table 19 : Medical Products Made of Animal-derived HA, 1997-2019
• Table 20 : Global Market for Hyaluronic Acid Medical Products, by Hyaluronic Acid Source, Through 2030
• Table 21 : Global Market for Hyaluronic Acid Medical Products, by Region, Through 2030
• Table 22 : North American Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 23 : North American Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 24 : HA Injectable Aesthetic Procedures Performed, by Country, 2023
• Table 25 : European Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 26 : European Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 27 : Asia-Pacific Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 28 : Asia-Pacific Market for Hyaluronic Acid Medical Products, by Country, Through 2030
• Table 29 : MEA Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 30 : South American Market for Hyaluronic Acid Medical Products, by Product, Through 2030
• Table 31 : Information Sources for this Report
• Table 32 : Abbreviations Used in This Report
• Table 33 : AbbVie Inc.: Company Snapshot
• Table 34 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 35 : AbbVie Inc.: Product Portfolio
• Table 36 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 37 : Anika Therapeutics Inc.: Company Snapshot
• Table 38 : Anika Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 39 : Anika Therapeutics Inc.: Product Portfolio
• Table 40 : Anika Therapeutics Inc.: News/Key Developments, 2023 and 2024
• Table 41 : Bioventus: Company Snapshot
• Table 42 : Bioventus: Financial Performance, FY 2023 and 2024
• Table 43 : Bioventus: Product Portfolio
• Table 44 : Bioventus: News/Key Developments, 2023
• Table 45 : Ferring B.V.: Company Snapshot
• Table 46 : Ferring B.V.: Financial Performance, FY 2023 and 2024
• Table 47 : Ferring B.V.: Product Portfolio
• Table 48 : Fidia Farmaceutici S.p.A.: Company Snapshot
• Table 49 : Fidia Farmaceutici S.p.A.: Financial Performance, FY 2023 and 2024
• Table 50 : Fidia Farmaceutici S.p.A.: Product Portfolio
• Table 51 : Fidia Farmaceutici S.p.A.: News/Key Developments, 2023 and 2024
• Table 52 : Galderma: Company Snapshot
• Table 53 : Galderma: Financial Performance, FY 2023 and 2024
• Table 54 : Galderma: Product Portfolio
• Table 55 : Galderma: News/Key Developments, 2023 and 2024
• Table 56 : IBSA Institut Biochimique SA: Company Snapshot
• Table 57 : IBSA Institut Biochimique SA: Product Portfolio
• Table 58 : IBSA Institut Biochimique SA: News/Key Developments, 2024
• Table 59 : Medytox: Company Snapshot
• Table 60 : Medytox: Financial Performance, FY 2023 and 2024
• Table 61 : Medytox: Product Portfolio
• Table 62 : Merz Pharma: Company Snapshot
• Table 63 : Merz Pharma: Product Portfolio
• Table 64 : Nordic Pharma: Company Snapshot
• Table 65 : Nordic Pharma: Product Portfolio
• Table 66 : Nordic Pharma: News/Key Developments, 2023-2025
• Table 67 : Sanofi: Company Snapshot
• Table 68 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 69 : Sanofi: Product Portfolio
• Table 70 : Santen Pharmaceutical Co. Ltd.: Company Snapshot
• Table 71 : Santen Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 72 : Santen Pharmaceutical Co. Ltd.: Product Portfolio
• Table 73 : Seikagaku Corp.: Company Snapshot
• Table 74 : Seikagaku Corp.: Financial Performance, FY 2023 and 2024
• Table 75 : Seikagaku Corp.: Product Portfolio
• Table 76 : Seikagaku Corp.: News/Key Developments, 2024 and 2025
• Table 77 : Teoxane: Company Snapshot
• Table 78 : Teoxane: Product Portfolio
• Table 79 : URSAPHARM Arzneimittel GmbH: Company Snapshot
• Table 80 : URSAPHARM Arzneimittel GmbH: Product Portfolio
• Table 81 : List of a Few Emerging Startups/Market Disruptors

List of Figures

• Summary Figure : Global Market Shares of Hyaluronic Acid Medical Products, by Region, 2024
• Figure 1 : Key Properties of Hyaluronic Acid
• Figure 2 : Porter's Five Forces Analysis - Hyaluronic Acid in Healthcare Market
• Figure 3 : Market Dynamics for Hyaluronic Acid in Healthcare
• Figure 4 : Active Clinical Trials for Hyaluronic Acid, by Indication Type, 2025
• Figure 5 : Global Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 6 : Global Market Shares of Viscosupplements, by Regimen Type, 2024
• Figure 7 : Global Market Shares of Ophthalmic Products, by Type, 2024
• Figure 8 : Global Market Shares of Hyaluronic Acid Medical Products, by Hyaluronic Acid Source, 2024
• Figure 9 : Global Market Shares of Hyaluronic Acid Medical Products, by Region, 2024
• Figure 10 : North American Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 11 : North American Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 12 : European Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 13 : European Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 14 : Asia-Pacific Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 15 : Asia-Pacific Market Shares of Hyaluronic Acid Medical Products, by Country, 2024
• Figure 16 : MEA Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 17 : South American Market Shares of Hyaluronic Acid Medical Products, by Product, 2024
• Figure 18 : Global Market Shares of Hyaluronic Acid Dermal Fillers, by Company, 2024
• Figure 19 : Global Market Shares of Viscosupplements, by Company, 2024
• Figure 20 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 21 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 22 : Anika Therapeutics Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 23 : Anika Therapeutics Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 24 : Bioventus: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Bioventus: Revenue Share, by Country/Region, FY 2024
• Figure 26 : Ferring B.V.: Revenue Share, by Business Unit, FY 2024
• Figure 27 : Ferring B.V.: Revenue Share, by Country/Region, FY 2024
• Figure 28 : Fidia Farmaceutici S.p.A.: Revenue Share, by Business Unit, FY 2024
• Figure 29 : Fidia Farmaceutici S.p.A.: Revenue Share, by Country/Region, FY 2024
• Figure 30 : Galderma: Revenue Share, by Business Unit, FY 2024
• Figure 31 : Galderma: Revenue Share, by Country/Region, FY 2024
• Figure 32 : Medytox: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Medytox: Revenue Share, by Country/Region, FY 2024
• Figure 34 : Sanofi: Revenue Share, by Business Unit, FY 2024
• Figure 35 : Sanofi: Revenue Share, by Country/Region, FY 2024
• Figure 36 : Santen Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 37 : Santen Pharmaceutical Co. Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 38 : Seikagaku Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 39 : Seikagaku Corp.: Revenue Share, by Country/Region, FY 2024